Olema Pharmaceuticals (OLMA) Change in Account Payables (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Change in Account Payables data on record, last reported at -$5.7 million in Q1 2026.

  • On a quarterly basis, Change in Account Payables fell 31.84% to -$5.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 147.74% increase, with the full-year FY2025 number at $4.6 million, up 83.19% from a year prior.
  • Change in Account Payables reached -$5.7 million in Q1 2026 per OLMA's latest filing, down from $5.8 million in the prior quarter.
  • Over the last five years, Change in Account Payables for OLMA hit a ceiling of $5.8 million in Q4 2025 and a floor of -$5.7 million in Q1 2026.
  • A 5-year average of $241294.1 and a median of $360000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 3060.0% in 2022, then surged 1514.98% in 2024.
  • Tracing OLMA's Change in Account Payables over 5 years: stood at $360000.0 in 2022, then skyrocketed by 36.39% to $491000.0 in 2023, then soared by 413.85% to $2.5 million in 2024, then surged by 128.81% to $5.8 million in 2025, then tumbled by 198.41% to -$5.7 million in 2026.
  • Business Quant data shows Change in Account Payables for OLMA at -$5.7 million in Q1 2026, $5.8 million in Q4 2025, and $2.4 million in Q3 2025.